ClinicalTrials.gg
CompletedNCT00914641Updated Aug 25, 2009

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

A Phase 1 interventional study of Apixaban IR and Apixaban MR1 in Thrombosis, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-25.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing apixaban in Thrombosis — 5 open to participants now, 5 under way, 2 of them phase 3. apixaban · Thrombosis.

Enrollment
17th of 18
16 · median 73
Started
2009
the only one that year
Phase 1
4 of 18
1 open now
Registered
1st of 18
by date

Among the 18 studies testing apixaban in Thrombosis, this one is the 17th largest by enrollment, is the only one that started in 2009, is one of 4 in phase 1, and was the 1st registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

5 of the 18 studies testing apixaban in Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing apixaban in Thrombosis, or all of them as a file.
02

Study summary

To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet

03

Conditions studied

  • Thrombosis

Browse trials for

Keywords

  • formulation; sustained release; modified release; extended release
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female patients
  • (BMI) of 17.5 to 30.5 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • History or evidence of abnormal bleeding or clotting disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Apixaban Cross-over

    Drug: Apixaban IR · Drug: Apixaban MR1 · Drug: Apixaban MR2 · Drug: Apixaban MR3

Interventions

  • immediate release tablet, 10 mg, single dose

  • DrugApixaban MR1

    modified release tablet 1, 10 mg, single dose

  • DrugApixaban MR2

    modified release tablet 2, 10 mg, single dose

  • DrugApixaban MR3

    modified release tablet 3, 10 mg, single dose

06

What researchers measure

Primary outcomes

  1. Apixaban PK: Cmax, C24, AUClast, AUCinf, Tmax, and half-life (t½)

    Time frame: 96 hours

  2. Safety and tolerability as determined by adverse event reporting, clinical laboratory results, vital signs, physical examinations, and ECGs.

    Time frame: per treatment period of 96 hours

07

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2009
First posted
Jun 5, 2009
Start
Jun 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Aug 25, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00914641
Lead sponsor
Pfizer
First posted
Jun 5, 2009
Start date
Jun 2009
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Aug 25, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion